Article | July 20, 2022

The AI Revolution In Multivigilance

By Bruce Palsulich, Vice President, Product Strategy

Artificial Intelligence GettyImages-1319573751

The life science industry is undergoing dynamic change thanks to advances in science and engineering. Companies are developing, testing, and marketing medicines based on new technologies that promise to treat everything from cancer to rare genetic conditions more effectively than ever. At the same time, the costs of R&D have exploded. Bringing a therapy from the lab through approvals takes more than a decade, on average, at an overall investment of more than $2.6 billion, according to industry estimates.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader